Pharma co Dr Reddy’s to reduce costs

HYDERABAD: Even as the threat of US tariffs on pharma imports looms large, Dr Reddy’s Laboratories is wielding the axe to cut flab and lower costs.

It is learnt that the company is laying off senior employees earning hefty packages across departments and also shutting down or rationalising headcount in certain businesses.

It is working on a target to cut workforce costs by 25% by laying off around 300-400 employees. It has asked many employees with annual pay packages of over Rs 1 crore to leave as part of the exercise. This is expected to lead to savings of up to Rs 1,300 crore, said a report.

Related Posts

  • Pharma
  • April 28, 2025
  • 16 views
Gujrat leads pharma sector with record 183 new plants

Ahmedabad:  Gujarat has further cemented its position as India’s pharmaceutical powerhouse with the state’s Food and Drug Control Administration (FDCA) approving 183 new allopathic drug manufacturing facilities in FY 2024-25,…

  • Pharma
  • April 28, 2025
  • 65 views
Doctor not liable for prescribing costly drug: HC

Cuttack:  Orissa high court has ruled that a doctor should not be held criminally liable for prescribing a particular drug of any pharmaceutical company for treatment of a disease like…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gujrat leads pharma sector with record 183 new plants

Gujrat leads pharma sector with record 183 new plants

Doctor not liable for prescribing costly drug: HC

Doctor not liable for prescribing costly drug: HC

878 Tramadol capsules being smuggled in Scorpio seized, three arrested

878 Tramadol capsules being smuggled in Scorpio seized, three arrested

Doctor not criminally liable for prescribing costly drug: Orissa High Court

Doctor not criminally liable for prescribing costly drug: Orissa High Court

Merger of Suven Pharma, Cohance Lifesciences to take effect from May 1

Merger of Suven Pharma, Cohance Lifesciences to take effect from May 1

Dr Lal PathLabs Q4 profit rises 81% on volume growth, geographic expansion

Dr Lal PathLabs Q4 profit rises 81% on volume growth, geographic expansion